Cancer

ASCO: Trametinib improves survival in metastatic melanoma

(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free ...

Cancer

An 'evolutionary relic' of the genome causes cancer

Pseudogenes, a sub-class of long non-coding RNA (lncRNA) that developed from the genome's 20,000 protein-coding genes but lost the ability to produce proteins, have long been considered nothing more than genomic "junk." Yet ...

Cancer

Melanoma cells rewire to resist drug treatment

In 2014, new combination therapies to treat patients with metastatic melanoma hit the market, helping extend the lives of those with this aggressive disease. Yet unfortunately, after several months of treatment, almost all ...

Cancer

The coming third wave of precision cancer medicines

Targeted treatments for cancer have been extending and saving lives for more than 15 years—precision medicine isn't a new idea in oncology. Now drugs pioneered on select, specific cancers are, one by one, finding new applications.

page 1 from 9